Topic: mergers and acquisitions
The all-stock deal will give Kiadis control of a preclinical natural killer cell therapy and see it add CAR-T pioneer Carl June to its scientific advisory board.
Looking to boost its offerings in central nervous system trials, Evolution Research Group has bought up New York-based Finger Lakes Clinical Research.
Novartis is picking up one clinical-stage and two preclinical NLRP3 antagonist programs in its acquisition of IFM Tre.
It was a $6 billion deal that was meant to help bolster AbbVie’s pipeline, but Stemcentrx has proven to be a major thorn in its side.
Guardant Health has moved to acquire Bellwether Bio, which focuses on early cancer diagnostics that tap into the epigenomics of cell-free DNA.
Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.
Fresenius’ new global medical office will head up its work in clinical science and coordinate the company’s global network of clinics.
The level of interest in gene therapies has been laid bare by a report on Biogen’s pursuit of Nightstar Therapeutics.
Novartis’ Alcon unit is picking up 2016 Fierce 15 company PowerVision in a $285 million deal for its flexible, fluid-based intraocular lens.
Stryker has acquired OrthoSpace, developers of a therapy for severely torn rotator cuffs, in a deal worth up to $220 million.
